Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25735646,apparent clearance (CL/F),CZP antibodies were treated as a structural model covariate and caused apparent clearance (CL/F) to increase from 0.685 to 2.74 L/day.,Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25735646/),[l] / [d],0.685,141830,DB08904,Certolizumab pegol
,25735646,apparent clearance (CL/F),CZP antibodies were treated as a structural model covariate and caused apparent clearance (CL/F) to increase from 0.685 to 2.74 L/day.,Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25735646/),[l] / [d],2.74,141831,DB08904,Certolizumab pegol
,25735646,CL/F,Albumin influenced CZP CL/F in a nonlinear fashion; CL/F decreased from 1.05 to 0.613 L/day with increasing albumin concentrations in antibody-negative patients.,Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25735646/),[l] / [d],1.05,141832,DB08904,Certolizumab pegol
,25735646,CL/F,Albumin influenced CZP CL/F in a nonlinear fashion; CL/F decreased from 1.05 to 0.613 L/day with increasing albumin concentrations in antibody-negative patients.,Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25735646/),[l] / [d],0.613,141833,DB08904,Certolizumab pegol
,29030361,minimal CZP level,"Of the remaining 14 infants, 13 had no quantifiable CZP levels at birth (<0.032 μg/mL), and 1 had a minimal CZP level of 0.042 μg/mL (infant/mother plasma ratio 0.0009); no infants had quantifiable CZP levels at weeks 4 and 8.","Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29030361/),[μg] / [ml],0.042,195894,DB08904,Certolizumab pegol
,28353055,absorption rate constant,"Parameter estimates were absorption rate constant 1.83/day, CL/F 0.527 L/day, and apparent volume of distribution (V/F) 8.33 L. ADAb concentration (2.5-214 units/mL) increased the median CL/F by 142-174%.",Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353055/),1/[d],1.83,224226,DB08904,Certolizumab pegol
,28353055,CL/F,"Parameter estimates were absorption rate constant 1.83/day, CL/F 0.527 L/day, and apparent volume of distribution (V/F) 8.33 L. ADAb concentration (2.5-214 units/mL) increased the median CL/F by 142-174%.",Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353055/),[l] / [d],0.527,224227,DB08904,Certolizumab pegol
,28353055,apparent volume of distribution (V/F),"Parameter estimates were absorption rate constant 1.83/day, CL/F 0.527 L/day, and apparent volume of distribution (V/F) 8.33 L. ADAb concentration (2.5-214 units/mL) increased the median CL/F by 142-174%.",Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353055/),l,8.33,224228,DB08904,Certolizumab pegol
,17516714,elimination half-life,"The elimination half-life of certolizumab in humans has been extended to approximate/= 2 weeks through pegylation, allowing subcutaneous administration of this agent once every 4 weeks.",Certolizumab pegol: in Crohn's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516714/),weeks,2,258688,DB08904,Certolizumab pegol
